TrialESMO open2026

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

S Jacob et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.